CG Oncology, Inc. Financing Cash Flow
CG Oncology, Inc. (CGON) reported Financing Cash Flow of $394.92 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- CG Oncology, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $1.92M.
- CG Oncology, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $393.00M, a 87232.89% increase year-over-year.
- CG Oncology, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $99.07M, a 55.66% decline year-over-year.
- CG Oncology, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $54.37M, a 2409.00% increase year-over-year.
- CG Oncology, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $153.59M, a 75.55% decline from fiscal 2024.
- CG Oncology, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $628.28M, a 622.18% increase from fiscal 2023.
- CG Oncology, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $87.00M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $394.92M 10-Q · filed 2026-08-06 | $493.99M derived: sum of 3 quarters · filed 2026-08-06 | $548.36M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $393.00M 10-Q · filed 2026-05-08 | $492.06M derived: sum of 2 quarters · filed 2026-05-08 | $546.43M derived: sum of 3 quarters · filed 2026-05-08 | $546.14M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $99.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $153.44M derived: sum of 2 quarters · filed 2026-02-27 | $153.14M derived: sum of 3 quarters · filed 2026-08-06 | $153.59M 10-K · filed 2026-02-27 |
| 2025-09-30 | $54.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $54.07M derived: sum of 2 quarters · filed 2026-08-06 | $54.52M 10-Q · filed 2025-11-14 | $277.94M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$296.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $154.00K 10-Q · filed 2026-08-06 | $223.57M derived: sum of 3 quarters · filed 2026-08-06 | $225.74M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $450.00K 10-Q · filed 2026-05-08 | $223.86M derived: sum of 2 quarters · filed 2026-05-08 | $226.03M derived: sum of 3 quarters · filed 2026-05-08 | $226.07M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $223.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $225.58M derived: sum of 2 quarters · filed 2026-02-27 | $225.62M derived: sum of 3 quarters · filed 2026-02-27 | $628.28M 10-K · filed 2026-02-27 |
| 2024-09-30 | $2.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $2.21M derived: sum of 2 quarters · filed 2025-11-14 | $404.87M 10-Q · filed 2025-11-14 | $401.97M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $40.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $402.70M 10-Q · filed 2025-08-08 | $399.80M derived: sum of 3 quarters · filed 2026-02-27 | $505.69M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $402.66M 10-Q · filed 2025-05-13 | $399.76M derived: sum of 2 quarters · filed 2026-02-27 | $505.64M derived: sum of 3 quarters · filed 2026-02-27 | $490.42M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | -$2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $102.99M derived: sum of 2 quarters · filed 2026-02-27 | $87.76M derived: sum of 3 quarters · filed 2026-02-27 | $87.00M 10-K · filed 2026-02-27 |
| 2023-09-30 | $105.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $90.66M derived: sum of 2 quarters · filed 2024-11-12 | $89.89M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$15.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$15.99M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | -$765.00K 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |